Humana (HUM) Stock Forecast & Price Target

Humana is well-positioned for margin expansion in Medicare Advantage, with analysts citing two 2027 levers that could lift EPS to $11.73-18.86 and an estimated $0.87-4.46 from cohort ’25 & earlier plus $1.87-5.40 from cohort ’26. Confidence is reinforced by better-than-feared 2027 cut points, reiteration of 2026 guidance, and the potential for top-quartile Bonus Year 2028 Stars performance, while CenterWell and Medicaid are expected to contribute about $2.17 of the 2028 EPS improvement. The stock also appears inexpensive relative to its long-term history, trading at 9.9x the implied $40.45 mid-point of its ’28 framework versus an approximately 18x P/E over the last 3, 5, and 10 years.

Humana is exposed to a concentrated reliance on Medicare Advantage, Medicaid, and Tricare, so any reimbursement reductions, benchmark cuts, or home-visit coding changes could quickly pressure the core franchise. The cited 25.0% y/y Individual MA growth and 60-70% cohort exposure may sound supportive, but it also raises the risk that 2026 membership gains will steepen the MLR slope as higher-morbidity members age out and lower-quality age-ins replace them, while non-inpatient competition rates of 90.0% in January and 80.0% in February signal a tougher pricing backdrop. Even if benefit design actions and Stars initiatives lift margins by 25-100bps and Group MA improves by 500 BPS in 2026, those gains may be offset by 10-30% attrition, low deferred-care visibility, and competitive pressure that could keep the stock fundamentally vulnerable.